Development of reusable logic for determination of statin exposure-time from electronic health records

Journal of Biomedical Informatics

Volumn 49, Issue , 2014, Pages 206-212

  Miller, Aaron W ^a   McCarty, Catherine A ^b   Broeckel, Ulrich ^c   Hytopoulos, Vangelis ^d   Cross, Deanna S ^e  

^a MARSHFIELD CLINIC   (United States)

^b ESSENTIA INSTITUTE OF RURAL HEALTH   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d Aviir Inc   (United States)

^e UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Algorithm; Anticholesteremic agents; Drug dosage calculations; Electronic health records; HMG CoA; Statins

Indexed keywords

ABSTRACTING; DRUG DOSAGE; ITERATIVE METHODS; RECORDS MANAGEMENT;

COORDINATION SYSTEMS; ELECTRONIC HEALTH RECORD; ELECTRONIC RECORDS; HMG-COA; HMG-COA REDUCTASE INHIBITOR; PERSONALIZED MEDICINES; STANDARD DEVIATION; STATINS;

ALGORITHMS;

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALGORITHM; ARTICLE; CORRELATION ANALYSIS; DRUG EXPOSURE; ELECTRONIC MEDICAL RECORD; GOLD STANDARD; HUMAN; LOGIC; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MEDICAL RECORD REVIEW; PRESCRIPTION; PRIORITY JOURNAL; THEORETICAL MODEL; VALIDATION STUDY;

ALGORITHMS; ELECTRONIC HEALTH RECORDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, THEORETICAL;

EID: 84902547661     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2014.02.014     Document Type: Article

References (48)

1. Miriovsky B.J., Shulman L.N., Abernethy A.P. Importance of health information technology, electronic health records, and continuously aggregating data to comparative effectiveness research and learning health care. J Clin Oncol 2012, 30:3243-3248.
2. Manion F.J., Harris M.R., Buyuktur A.G., et al. Leveraging. EHR data for outcomes and comparative effectiveness research in oncology. Curr Oncol Rep 2012, 14:494-501.
3. Kaushal R., Barron Y., Abramson E.L. The comparative effectiveness of 2 electronic prescribing systems. Am J Manag Care 2011, 17:SP88-SP94.
4. Nichols G.A., Desai J., Elston Lafata J., et al. Construction of a multisite DataLink using electronic health records for the identification, surveillance, prevention, and management of diabetes mellitus: the SUPREME-DM project. Prev Chronic Dis 2012, 9:E110.
5. Peissig P.L., Rasmussen L.V., Berg R.L., et al. Importance of multi-modal approaches to effectively identify cataract cases from electronic health records. J Am Med Inform Assoc 2012, 19:225-234.
6. Kho A.N., Hayes M.G., Rasmussen-Torvik L., et al. Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J Am Med Inform Assoc 2012, 19:212-218.
7. Rasmussen-Torvik L.J., Pacheco J.A., Wilke R.A., et al. High density GWAS for LDL cholesterol in African Americans using electronic medical records reveals a strong protective variant in APOE. Clin Transl Sci 2012, 5:394-399.
8. Carroll R.J., Thompson W.K., Eyler A.E., et al. Portability of an algorithm to identify rheumatoid arthritis in electronic health records. J Am Med Inform Assoc 2012, 19:e162-e169.
9. Kaelber D.C., Foster W., Gilder J., et al. Patient characteristics associated with venous thromboembolic events: a cohort study using pooled electronic health record data. J Am Med Inform Assoc 2012, 19:965-972.
10. Pantalone K.M., Kattan M.W., Yu C., et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab 2012, 14:803-809.
11. Reed M., Huang J., Graetz I., et al. Outpatient electronic health records and the clinical care and outcomes of patients with diabetes mellitus. Ann Intern Med 2012, 157:482-489.
12. Lillebo B., Seim A., Vinjevoll O.P., et al. What is optimal timing for trauma team alerts? A retrospective observational study of alert timing effects on the initial management of trauma patients. J Multidiscip Healthc 2012, 5:207-213.
13. Hripcsak G., Albers D.J. Next-generation phenotyping of electronic health records. J Am Med Inform Assoc 2012, 20:117-121.
14. Conway M., Berg R.L., Carrell D., et al. Analyzing the heterogeneity and complexity of Electronic Health Record oriented phenotyping algorithms. AMIA Annu Symp Proc 2011, 2011:274-283.
15. Kho A.N., Pacheco J.A., Peissig P.L., et al. Electronic medical records for genetic research: results of the eMERGE consortium. Sci Transl Med 2011, 3:79re1.
16. McCarty C.A., Chisholm R.L., Chute C.G., et al. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics 2011, 4:13.
17. Schildcrout J.S., Basford M.A., Pulley J.M., et al. An analytical approach to characterize morbidity profile dissimilarity between distinct cohorts using electronic medical records. J Biomed Inform 2010, 43:914-923.
18. Olson M.D., Tong G.L., Steiner B.D., et al. Medication documentation in a primary care network serving North Carolina medicaid patients: results of a cross-sectional chart review. BMC Fam Pract 2012, 13:83.
19. Nelson S.J., Brown S.H., Erlbaum M.S., et al. A semantic normal form for clinical drugs in the UMLS: early experiences with the VANDF. Proc AMIA Symp 2002, 2002:557-561.
20. SoRelle R. New lipid-lowering combo proves successful. Circulation 2003, 107:e9043-e9044.
21. Solomon L. Scored tablets make pill splitting easier. Am J Manag Care 2007, 13:e4.
22. Rosenau P.V., Lal L.S., Glasser J.H. U.S. pharmacy policy: a public health perspective on safety and cost. Soc Work Public Health 2009, 24:543-567.
23. Daskalopoulou S.S., Doonan R.J., Delaney J.A., et al. Different patterns of statin use in patients with acute myocardial infarction. Curr Vasc Pharmacol 2012, (September):18.
24. Daskalopoulou S.S., Delaney J.A., Filion K.B., et al. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008, 29:2083-2091.
25. Lee H.Y., Cooke C.E., Robertson T.A. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 2008, 14:271-280.
26. Zhou Z., Rahme E., Abrahamowicz M., et al. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ 2005, 172:1187-1194.
27. IMS Institute for Health Informatics. The use of medicines in the United States: review of 2010. Updated April 2011. <> [accessed 21.09.11]. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/IMS%20Institute/Static%20File/IHII_UseOfMed_report.pdf.
28. Jukema J.W., Cannon C.P., de Craen A.J., et al. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol 2012, 60:875-881.
29. Luz P.L., Nishiyama M., Chagas A.C. Drugs and lifestyle for the treatment and prevention of coronary artery disease: comparative analysis of the scientific basis. Braz J Med Biol Res 2011, 44:973-991.
30. Ma Y., Culver A., Rossouw J., et al. Statin therapy and the risk for diabetes among adult women: do the benefits outweigh the risk?. Ther Adv Cardiovasc Dis 2012, 7:41-44.
31. Lee J., Lee S.H., Hur K.Y., et al. Statins and the risk of gastric cancer in diabetes patients. BMC Cancer 2012, 12:596.
32. Waters D.D., Ho J.E., Boekholdt S.M., et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2012, 61:148-152.
33. Rocco M.B. Statins and diabetes risk: fact, fiction, and clinical implications. Cleve Clin J Med 2012, 79:883-893.
34. Leung H.W., Chan A.L., Lo D., et al. Common cancer risk and statins: a population-based case-control study in a Chinese population. Expert Opin Drug Saf 2012, 12:19-27.
35. Prignot J. Quantification and chemical markers of tobacco-exposure. Eur J Respir Dis 1987, 70:1-7.
36. Love B.B., Biller J., Jones M.P., et al. Cigarette smoking. A risk factor for cerebral infarction in young adults. Arch Neurol 1990, 47:693-698.
37. Smith MEB, Lee NJ, Haney E, et al. Drug class review: HMG-CoA reductase inhibitors (statins). Update 5. <>. http://derp.ohsu.edu/about/final-document-display.cfm.
38. Greenlee R.T. Measuring disease frequency in the Marshfield Epidemiologic Study Area (MESA). Clin Med Res 2003, 1:273-280.
39. DeStefano F., Eaker E.D., Broste S.K., et al. Epidemiologic research in an integrated regional medical care system: the Marshfield Epidemiologic Study Area. J Clin Epidemiol 1996, 49:643-652.
40. McCarty C.A., Wilke R.A., Giampietro P.F., et al. Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank. Personal Med 2005, 2:49-79.
41. Strobush L., Berg R.L., Cross D., et al. Dietary intake in the Personalized Medicine Research Project: a resource for studies of gene-diet interaction. Nutr J 2011, 10:13.
42. Sirohi E., Peissig P. Study of effects of drug lexicons on medication extraction from electronic medical records. Pac Symp Biocomput 2005, 308-318.
43. NDDF PLUSTM Documentation Feb04. FirstDataBank; 2004.
44. TeSSI® for Healthcare and Life Sciences, Language and Computing. <> [accessed August 2011]. http://www.landc.be.
45. Peissig P., Sirohi E., Berg R.L., et al. Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank. Basic Clin Pharmacol Toxicol 2007, 100:286-288.
46. Engels J.M., Diehr P. Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol 2003, 56:968-976.
47. Cars T., Wettermark B., Malmström R.E., et al. Extraction of electronic health record data in a hospital setting: comparison of automatic and semi-automatic methods using anti-TNF therapy as model. Basic Clin Pharmacol Toxicol 2013, 112:392-400.
48. Bennett C.C. Utilizing RxNorm to support practical computing applications: capturing medication history in live electronic health records. J Biomed Inform 2012, 45:634-641.